▶ KISSPEPTIN-10 · SUBTOPIC · SAFETY PROFILE

KISSPEPTIN-10 Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of KISSPEPTIN-10.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of KISSPEPTIN-10. Severity, frequency, and attribution depend on the source publication.

• Generally well-tolerated at research doses
• Mild injection-site discomfort

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for KISSPEPTIN-10.

• Other GnRH-axis modulators (GnRH agonists/antagonists, hCG)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for KISSPEPTIN-10 in the published record:

• Active sex-hormone-sensitive malignancy

FDA REGULATORY STATUS

Not FDA-approved. Research-use only in the United States.

WADA REGULATORY STATUS

Not specifically named on the 2024 Prohibited List. GnRH-axis-active compounds (e.g., hCG) are prohibited for male athletes under S2; kisspeptin may fall under regulator discretion.

SAFETY Q+A FROM LITERATURE

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

• Dhillo WS, Chaudhri OB, Patterson M, et al.. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005. PMID 15883247. link
• de Roux N, et al.. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003. PMID 12944565. link

RELATED PAGES

▶ LAST UPDATED · 2026-05-19